Christoph U Correll (Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA) shares his expert insights on the rationale for combined therapy with olanzapine and samidorphan for the management of patients with schizophrenia. He also provides an overview of the key efficacy and safety findings of the recent phase III ENLIGHTEN-2 study, which evaluated weight gain with ALKS 3831 (olanzapine and samidorphan) versus olanzapine in adult subjects with schizophrenia (ClinicalTrials.gov Identifier: NCT02694328).
Questions
1. What are the limitations of current second-generation antipsychotics in the treatment of patients with schizophrenia? (0:08)
2. What is the rationale for combined therapy with olanzapine and samidorphan? (1:03)
3. Could you please give us an overview of the aims, design and inclusion criteria of the ENLIGHTEN-2 study? (1:59)
See also the 2nd part of this interview: Christoph U Correll – Phase III ENLIGHTEN-2 Study in Schizophrenia (Part 2)
Disclosures: Prof. Correll has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva; he has provided expert testimony for Janssen and Otsuka; he has served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus and Teva; he has received grant support from Janssen and Takeda; and he is also a stock option holder of LB Pharma.
Support: Interview and filming supported by Touch Medical Media.
